Canaccord Genuity analyst Kyle Mikson CFA maintained a Hold rating on Quantum-Si yesterday and set a price target of $2.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kyle Mikson CFA’s rating is based on Quantum-Si’s recent performance and future prospects. The company’s third-quarter results were largely in line with expectations, although sales of its Platinum instruments fell short due to uncertainties in NIH funding. Despite these challenges, Quantum-Si has successfully expanded its customer base through alternative capital acquisition programs, particularly in academia.
Furthermore, the company is making progress on key pipeline products, including the upcoming launch of its version 3 Library Preparation Kit and successful sequencing runs on a prototype Proteus system. While these developments are promising, the persistent macroeconomic headwinds and the time required to fully capitalize on the protein sequencing market contribute to the Hold rating. The upcoming Investor & Analyst Day in November 2025 is anticipated to provide further insights, potentially influencing future stock performance.
In another report released today, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $2.00 price target.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QSI in relation to earlier this year.